Radius Ventures

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Impliant Ltd. and over $50 million have been invested in laboratory testing and clinical work to perfect the implant, the instrumentation, and the surgical technique. The TOPS(TM) System aims to revolutionize the spinal implant market in much the same way that total hip and total knee replacement systems displaced hip and knee fusions. Premia Spine's singular focus today is to provide patients and surgeons with a clinically-proven superior solution to lumbar fusion surgery.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Tabula Rasa Healthcare, formerly known as CareKinesis, specializes in state-of-the-art medication management solutions that leverage technology, science, and services to enhance the quality of care, reduce costs, and mitigate risks associated with ineffective medication plans. Their innovative approach aims to optimize medication therapy for improved patient outcomes.

MID has developed the FloShield system, a franchise of products that substantially improve visualization during laparoscopic surgery. During laparoscopic surgery, it is common for condensation to form on the end of the laparoscope obscuring vision. It is also common for debris from the ultrasonic scalpel, cautery, or even blood products themselves to degrade the surgical view. Most commonly, surgeons will need to remove the laparoscope for manual cleaning. It was founded in 2006 and headquartered in Columbus, Ohio.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Tactile Medical is a medical technology company based in Minneapolis, Minnesota, specializing in the development and provision of medical devices aimed at treating chronic diseases. The company offers several innovative products, including the Flexitouch Plus system, a pneumatic compression device designed for lymphedema treatment, and the Entré System, a portable device for at-home management of venous disorders such as chronic venous insufficiency and venous leg ulcers. Additionally, Tactile Medical produces the ACTitouch system, which is targeted at patients suffering from chronic venous insufficiency, and the Airwear Gradient Compression Wrap, marketed as Aero-Wrap, for managing venous insufficiency and related conditions. Founded in 1995, Tactile Medical is committed to advancing the standard of care for patients dealing with edema and vascular diseases.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Usystems specializes in the design, development, and manufacture of advanced ultrasound systems and software aimed at enhancing breast cancer detection, particularly in women with dense breast tissue. The company's innovative products provide high-quality 3D ultrasound images that assist radiologists in identifying areas of concern within breast tissue. In addition to its focus on medical imaging, Usystems is dedicated to creating cutting-edge racking enclosures and cooling solutions that minimize noise, heat, and operational costs in data centers and office environments. Through a commitment to quality and innovation, Usystems employs state-of-the-art manufacturing processes to deliver effective solutions in both healthcare and data management sectors.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Healthsense, Inc. is a provider of remote monitoring solutions specifically designed for the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company specializes in health and safety monitoring systems that track essential daily activities such as eating, sleeping, toileting, and movement. Healthsense's technology includes analytics that transform data into actionable insights, a centralized dashboard, health notes that alert caregivers to behavioral changes, and real-time notifications for urgent needs. These solutions are aimed at enhancing the quality of care in senior living, managed care, and home care settings, ultimately promoting greater independence and improved experiences for seniors. As of late 2016, Healthsense operates as a subsidiary of GreatCall, Inc.

Management Health Solutions, Inc. (MHS) is a prominent provider of integrated inventory management solutions tailored for hospitals and healthcare systems in North America. Established in 1999 and headquartered in Fairfield, Connecticut, MHS focuses on reducing clinical supply inventory costs while streamlining supply chain operations. The company enhances patient safety and financial performance through a combination of professional services, content solutions, benchmarks, advanced technology, and mobile device management. By implementing its solutions, MHS helps healthcare organizations achieve measurable returns on investment, ultimately contributing to more efficient and effective clinical supply management.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Resolvyx Pharmaceuticals is developing an entirely new class of medicines called Resolvins. Resolvins are naturally-occurring, small molecule lipid mediators with the potential to treat a wide range of inflammatory diseases. Unlike most anti-inflammatory drugs which suppress the body's inflammatory response, Resolvins work by activating the body's own mechanisms for shutting off, or resolving, inflammation.

Medingo develops and produces miniature medical devices for people with diabetes. The company's flagship product is the Solo MicroPump, a tiny insulin pump that allows people with diabetes to deliver insulin discreetly without tubing or needles. The company was founded in 2005 and is based in Yoqneam Illit, Israel and the US Corporate Office is in Tampa, FL.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Usystems specializes in the design, development, and manufacture of advanced ultrasound systems and software aimed at enhancing breast cancer detection, particularly in women with dense breast tissue. The company's innovative products provide high-quality 3D ultrasound images that assist radiologists in identifying areas of concern within breast tissue. In addition to its focus on medical imaging, Usystems is dedicated to creating cutting-edge racking enclosures and cooling solutions that minimize noise, heat, and operational costs in data centers and office environments. Through a commitment to quality and innovation, Usystems employs state-of-the-art manufacturing processes to deliver effective solutions in both healthcare and data management sectors.

Athersys, Inc. is a biotechnology company based in Cleveland, Ohio, specializing in regenerative medicine. The company focuses on the research and development of therapeutic products aimed at treating various disease indications, including neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary issues. Athersys's primary product, MultiStem cell therapy, is an allogeneic stem cell treatment currently undergoing Phase III clinical trials for ischemic stroke and Phase II trials for acute myocardial infarction. Additionally, it has completed Phase I studies for treating leukemia and other blood-borne cancers. Athersys also explores applications of MultiStem in veterinary medicine for serious health conditions. The company maintains collaborative agreements with Healios K.K. and the University of Minnesota to expand the development and commercialization of its therapies. Revenue is generated through corporate partnerships, licensing agreements, and government grants.

BioStorage Technologies is the premier, global provider of comprehensive sample management solutions for the bioscience industry BioStorage Technologies, Inc. was founded in 2002 and is privately held and headquartered in North America in Indianapolis, Indiana with an additional full-service site in Europe near Frankfurt, Germany. Their mission is to provide their clients with world class, biorepository services, exceeding clients’ expectations of service, value and quality while setting the industry standard for the storage, management & logistics of samples.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Heartscape Technologies, Inc. develops and markets medical devices for hospitals in the United States. The company offers PRIME ECG System, a cardiac diagnostic system designed to diagnose heart attacks and ischemia. Its PRIME ECG System displays a range of images that allows a physician to detect potential problem areas and explore important details needed for diagnosis; and various test reports.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

EyeTel Imaging, founded in 1996, specializes in developing imaging technologies aimed at addressing vision loss caused by undetected diabetic retinopathy. The company signed a license agreement with Johns Hopkins University to commercialize new retinal imaging technology, leading to the creation of the EyeTel Retinal Imaging System, which is based on the DigiScope, a semi-automated fundus camera. This system enables the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images. Collaborating with the Wilmer Eye Institute, EyeTel has ensured extensive clinical validation of its products. The company has established manufacturing partnerships to produce the DigiScope cost-effectively, and its enhancements have made the system a reliable diagnostic tool for optometrists.

Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.

EyeTel Imaging, founded in 1996, specializes in developing imaging technologies aimed at addressing vision loss caused by undetected diabetic retinopathy. The company signed a license agreement with Johns Hopkins University to commercialize new retinal imaging technology, leading to the creation of the EyeTel Retinal Imaging System, which is based on the DigiScope, a semi-automated fundus camera. This system enables the detection of various ocular conditions, including age-related macular degeneration and glaucoma. EyeTel also operates the EyeTel Reading Center, a telemedicine service that offers expert analysis of patient images. Collaborating with the Wilmer Eye Institute, EyeTel has ensured extensive clinical validation of its products. The company has established manufacturing partnerships to produce the DigiScope cost-effectively, and its enhancements have made the system a reliable diagnostic tool for optometrists.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

NuGEN Technologies, Inc. specializes in developing and providing next-generation sequencing kits and genomic sample preparation reagents tailored for research and diagnostic applications within the genomics field. The company offers a diverse range of technologies that cater to various applications, including RNA-Seq, targeted resequencing, target capture, ChIP-Seq, and Methyl-Seq. Additionally, NuGEN's solutions are designed to analyze specimens of limited or poor quality, facilitating high throughput applications on leading analytical platforms such as microarrays and qPCR. The company is dedicated to advancing life sciences by delivering robust and reproducible results that aid researchers in predicting disease risk and drug responses, thereby potentially expediting treatment pathways. Founded in 2000 and based in San Carlos, California, NuGEN serves its customers through a network of distributors both domestically and internationally, and it operates as a subsidiary of Tecan Group Ltd.

Health Language specializes in enterprise terminology management solutions aimed at normalizing data across healthcare organizations. Founded in 2000 and based in Denver, Colorado, the company offers a suite of health management software, consulting services, and content that facilitates the mapping, translation, and management of clinical terminologies on a large scale. Its offerings include solutions for content standardization, data normalization, ICD-10 remediation, and enhanced workflows through streamlined search capabilities. By developing a proprietary middleware application, Health Language automates the integration of controlled medical vocabulary and coding standards into healthcare IT applications. This enables centralized access to medical terminology standards, promoting interoperability among hospitals, regions, and countries, and serving a diverse clientele that includes payers, providers, and vendors.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

NuGEN Technologies, Inc. specializes in developing and providing next-generation sequencing kits and genomic sample preparation reagents tailored for research and diagnostic applications within the genomics field. The company offers a diverse range of technologies that cater to various applications, including RNA-Seq, targeted resequencing, target capture, ChIP-Seq, and Methyl-Seq. Additionally, NuGEN's solutions are designed to analyze specimens of limited or poor quality, facilitating high throughput applications on leading analytical platforms such as microarrays and qPCR. The company is dedicated to advancing life sciences by delivering robust and reproducible results that aid researchers in predicting disease risk and drug responses, thereby potentially expediting treatment pathways. Founded in 2000 and based in San Carlos, California, NuGEN serves its customers through a network of distributors both domestically and internationally, and it operates as a subsidiary of Tecan Group Ltd.

TheScientificWorld is a scientific information portal established in 1997 and based in New York. It offers an integrated suite of resources designed to support scientists in their research and professional activities. The platform serves as a comprehensive hub for scientific information, facilitating access to various tools and resources that enhance the research experience for its users.

AMICAS, Inc. provides radiology, and medical image and information management solutions in the United States. Its AMICAS One Suite products provide an end-to-end IT solution for imaging centers, ambulatory care facilities, radiology practices, and billing services. The company offers AMICAS PACS, a Web-based picture archiving and communications system to capture, store, manipulate, and distribute diagnostic images for radiologists, specialists, referring physicians, patients, and healthcare enterprises; and AMICAS RIS, a Web-based radiology information system to capture radiology orders, detail the patient demographic information, schedule appointments and resources, process transcriptions, and generate reports, as well as to code and prepare billing and reimbursement data. It also provides AMICAS RadStream that offers integrated critical results management capabilities and document the communication of critical results reporting of radiology studies; AMICAS Documents, a module to capture, digitize, and associate paper records with digital information; and AMICAS Financials, which facilitates claims submission, payer follow-up, and other billing and accounts receivable management activities. In addition, the company offers AMICAS Reach, a Web-based tool that integrates the radiology report with key images; AMICAS Dashboards, a Web-based system that provides business intelligence capabilities; and AMICAS EDI offering transaction-based functions. Further, it provides professional and consulting services that assist its clients with a planned transition to a digital enterprise, as well as offers software and hardware support, implementation, training, and electronic data interchange services for patient billing and claims processing. The company was formerly known as VitalWorks Inc. and changed its name to AMICAS, Inc. in January 2005. AMICAS, Inc. was founded in 1989 and is headquartered in Boston, Massachusetts.